Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Petmed Express ( (PETS) ) has provided an announcement.
On September 8, 2025, PetMed Express, Inc.’s Board of Directors approved an initial annual base salary of $550,000 for Leslie C.G. Campbell, who began her role as Interim CEO and President on August 11, 2025. Additionally, the Board granted a restricted stock award of 10,000 shares to Douglas Krulik, the Chief Accounting Officer and Interim Principal Financial Officer, under the company’s 2024 Omnibus Incentive Plan, with the award vesting six months after the grant date.
The most recent analyst rating on (PETS) stock is a Sell with a $3.00 price target. To see the full list of analyst forecasts on Petmed Express stock, see the PETS Stock Forecast page.
Spark’s Take on PETS Stock
According to Spark, TipRanks’ AI Analyst, PETS is a Neutral.
Petmed Express shows a mixed financial performance with strong balance sheet stability but weak profitability and inconsistent cash flow. Technical analysis indicates a bearish trend with oversold conditions, while valuation metrics suggest the stock may be overvalued. The earnings call highlights progress in profitability and strategic investments, but challenges remain in sales and competitive pressures. Overall, the stock score reflects these combined factors, indicating moderate potential with significant risks.
To see Spark’s full report on PETS stock, click here.
More about Petmed Express
PetMed Express, Inc. operates in the pet pharmaceutical industry, providing prescription and non-prescription pet medications and other health products for dogs, cats, and horses. The company focuses on delivering these products directly to consumers through its online platform.
Average Trading Volume: 138,777
Technical Sentiment Signal: Sell
Current Market Cap: $58.46M
Find detailed analytics on PETS stock on TipRanks’ Stock Analysis page.